Vaxcyte Advances Pneumococcal Vaccine Trial, Eyes 2027 Data
Event summary
- Vaxcyte initiated the OPUS-3 Phase 3 trial evaluating VAX-31 in adults with prior pneumococcal vaccination, dosing the first participants on February 11, 2026.
- The trial aims to assess the safety, tolerability, and immunogenicity of VAX-31, specifically its ability to boost immune responses in previously vaccinated individuals.
- Vaxcyte anticipates topline data from the OPUS-3 and OPUS-2 trials (concomitant administration with a seasonal influenza vaccine) in the first half of 2027.
- The Phase 3 adult clinical program for VAX-31 involves approximately 6,000 adults across three trials, with the goal of supporting a Biologics License Application (BLA) submission.
- VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50+.
The big picture
Vaxcyte's VAX-31 represents a significant effort to address the ongoing challenge of pneumococcal disease, a major public health concern with rising antibiotic resistance. The broader coverage offered by VAX-31, potentially exceeding current standard-of-care vaccines by a substantial margin (14-34% for IPD, 19-31% for pneumonia), positions it to capture a significant share of the ~$3 billion global pneumococcal vaccine market if clinical trials prove successful. The company's reliance on its XpressCF platform for manufacturing consistency will be a key factor in scaling production and meeting potential demand.
What we're watching
- Regulatory Risk
- The FDA’s continued alignment with Vaxcyte’s development program will be crucial for a timely BLA submission, and any shifts in regulatory expectations could delay the process.
- Competitive Landscape
- The performance of VAX-31 relative to existing vaccines like Prevnar 20 and Pneumovax 23, particularly in boosting immune responses in previously vaccinated patients, will determine its market adoption.
- Execution Risk
- The successful enrollment and completion of the three Phase 3 trials, involving approximately 6,000 adults, within the projected timeframe will be essential for meeting the 2027 data reporting deadline.
Related topics